Top Page
Heartseed, Inc.
(219A)
Heartseed, Inc. (219A) vs. iShares MSCI Japan ETF (EWJ)
Heartseed, Inc. Business Overview & Revenue Model
Heartseed, Inc. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 2.64B | 873.61M | 344.73M | 499.06M |
| Gross Profit | 2.61B | 873.61M | 344.73M | 499.06M |
| EBITDA | 610.27M | -776.36M | -1.45B | -1.41B |
| Net Income | 519.32M | -812.73M | -1.47B | -1.41B |
Balance Sheet | ||||
| Total Assets | 7.71B | 7.07B | 5.72B | 4.94B |
| Cash, Cash Equivalents and Short-Term Investments | 6.92B | 5.30B | 4.59B | 3.99B |
| Total Debt | 2.04M | 5.39M | 11.58M | 30.98M |
| Total Liabilities | 508.69M | 444.35M | 450.19M | 208.45M |
| Stockholders Equity | 7.20B | 6.62B | 5.27B | 4.73B |
Cash Flow | ||||
| Free Cash Flow | 0.00 | -1.41B | -1.13B | -1.92B |
| Operating Cash Flow | 0.00 | -1.34B | -797.93M | -1.92B |
| Investing Cash Flow | 0.00 | -67.13M | -425.69M | -994.00K |
| Financing Cash Flow | 0.00 | 2.12B | 1.85B | -22.16M |
Heartseed, Inc. Technical Analysis
Heartseed, Inc. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ¥31.36B | 9.49 | ― | 6.75% | -3.11% | -13.09% | |
58 Neutral | ¥19.33B | -48.16 | ― | ― | -5.65% | -469.19% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | ¥16.96B | -8.77 | ― | ― | ― | 5.58% | |
45 Neutral | ¥39.76B | 75.52 | ― | ― | ― | ― | |
45 Neutral | ¥76.11B | -31.76 | ― | 3.47% | 7.15% | -454.41% | |
33 Underperform | ¥55.07B | -82.47 | ― | ― | 1242.62% | 2.56% |
Heartseed, Inc. Corporate Events
Heartseed Inc. announced the termination of its partnership with Novo Nordisk A/S, which was initially a significant collaboration in the cell therapy field. The company is addressing investor concerns about the impact on its stock price and future partnerships, emphasizing its recognition in the international market and the need for careful consideration in forming new alliances to enhance corporate value.
The most recent analyst rating on (JP:219A) stock is a Hold with a Yen3290.00 price target. To see the full list of analyst forecasts on Heartseed, Inc. stock, see the JP:219A Stock Forecast page.
Heartseed Inc. has announced the submission of a clinical trial notification to Japan’s Pharmaceuticals and Medical Devices Agency for its HS-005 therapy, marking a significant step towards treating severe heart failure. The trial aims to assess the safety and efficacy of the therapy in 14 patients, with plans to begin treatment in 2026, reflecting the company’s strategic progress in advancing regenerative cardiac therapies.
The most recent analyst rating on (JP:219A) stock is a Hold with a Yen3290.00 price target. To see the full list of analyst forecasts on Heartseed, Inc. stock, see the JP:219A Stock Forecast page.
Heartseed, Inc. announced the termination of its partnership with Novo Nordisk A/S, clarifying that no penalty will be incurred from the termination. The company retains its milestone payments and continues its development plans for its therapeutic programs in Japan, with no impact on its financial stability for upcoming clinical trials. The overseas strategy is under review, and the company will disclose further information in due course. Despite concerns about potential information leaks and stock trading volumes, Heartseed asserts no correlation between these events and the termination announcement.
The most recent analyst rating on (JP:219A) stock is a Hold with a Yen3290.00 price target. To see the full list of analyst forecasts on Heartseed, Inc. stock, see the JP:219A Stock Forecast page.
Heartseed Inc. announced the termination of its exclusive worldwide collaboration and license agreement with Novo Nordisk A/S, as Novo Nordisk shifts focus to its core business areas. The termination impacts Heartseed’s overseas business strategy and intellectual property management, but does not affect its ongoing clinical trials or technology development. The company will now receive 100% of sales revenue in Japan and plans to continue its development efforts domestically while exploring new overseas partnerships.
The most recent analyst rating on (JP:219A) stock is a Hold with a Yen3290.00 price target. To see the full list of analyst forecasts on Heartseed, Inc. stock, see the JP:219A Stock Forecast page.
Heartseed Inc. announced the termination of its partnership with Novo Nordisk A/S, which decided to concentrate on its core business areas. As a result, Heartseed regains worldwide rights to its therapeutic programs HS-001 and HS-005 for severe heart failure. The company maintains its earnings forecast for 2025 and reports no safety or efficacy concerns for HS-001, with HS-005 clinical preparations progressing as planned.
The most recent analyst rating on (JP:219A) stock is a Hold with a Yen3290.00 price target. To see the full list of analyst forecasts on Heartseed, Inc. stock, see the JP:219A Stock Forecast page.
Heartseed Inc. has announced a collaboration with Japan Lifeline Co., Ltd. for the supply of a delivery catheter system, which is crucial for their HS-005 clinical trial in Japan. The trial involves a catheter-based administration of allogeneic iPS cell-derived cardiomyocyte spheroids, and the company aims to submit the clinical trial application by the end of 2025, with no changes to their financial forecast.
The most recent analyst rating on (JP:219A) stock is a Hold with a Yen3791.00 price target. To see the full list of analyst forecasts on Heartseed, Inc. stock, see the JP:219A Stock Forecast page.
Heartseed Inc. reported significant financial improvements for the nine months ending July 31, 2025, with net sales reaching ¥1,919 million compared to ¥153 million in the previous year. This positive shift indicates a strong recovery and growth trajectory, enhancing the company’s market position and potentially benefiting its stakeholders.
The most recent analyst rating on (JP:219A) stock is a Hold with a Yen3791.00 price target. To see the full list of analyst forecasts on Heartseed, Inc. stock, see the JP:219A Stock Forecast page.
Heartseed Inc. has revised its full-year financial forecast for 2025, significantly increasing its net sales and profit expectations due to achieving a development milestone earlier than anticipated under its agreement with Novo Nordisk A/S. This milestone achievement has resulted in additional revenues, and the company also anticipates lower-than-expected expenses related to clinical trials and cell manufacturing, enhancing its financial outlook.
Heartseed Inc. announced that its stock has been newly selected as a Loan Margin Trading Issue on the Tokyo Stock Exchange Growth Market, effective August 14, 2025. This selection is expected to enhance the liquidity and trading activity of the company’s stock, potentially leading to fairer pricing and a better supply-demand balance.